Overview

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Status:
Completed
Trial end date:
2017-07-20
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Collaborator:
KuDOS Pharmaceuticals Limited
Treatments:
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Criteria
Inclusion Criteria:

- Advanced ovarian cancer with positive BRCA1 or BRCA2 status

- Failed at least one prior chemotherapy

- In investigators opinion, no curative standard therapy exists

- Measurable disease

Exclusion Criteria:

- Brain metastases

- Less than 28 days since last treatment used to treat the disease

- Considered a poor medical risk due to a serious uncontrolled disorder